Key facts
- Varicula Biotec’s last known valuation is $15.8M (Dec 2024).
- It has raised $2.9M; the latest was Later Stage VC ($2.1M) in Dec 2024.
- Notable investors include Mittelständische Beteiligungsgesellschaft Mecklenburg-Vorpommern.
- Status: Privately Held (backing).
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Varicula Biotec
- ·The full record, as it builds
Funding rounds
No funding rounds for Varicula Biotec are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Varicula Biotec
Developer of an immuno-oncological drug intended to support the repair mechanisms of damaged cells. The company offers a strong immunomodulatory biologic with an understanding of the immune system and ttherapeutic drugs, enabling patients to help in their treatment.
- Sector
- Healthcare
- HQ
- Wismar, Germany
- Founded
- 2012
- Employees
- 7
- Website
- varicula.de/
- Ownership
- Privately Held (backing)
Varicula Biotec doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Varicula Biotec shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Varicula Biotec in its N-PORT filings yet. We sweep new filings monthly.